Alvotech Strikes $45m Deal With Yas Holding

Biosimilars Deal Includes 2.5% Stake And MENA Rights

Alvotech has struck an investment deal worth $45m that will give Yas Holding a 2.5% stake in the business, as well as rights to sell three Alvotech biosimilars in the MENA region.

Syringe
The deal gives Alvotech another injection of cash following Fuji Pharma’s $50m investment announced last year • Source: Shutterstock

Alvotech has struck a deal with United Arab Emirates-based “business development and investment group” Yas Holding that will give Yas a 2.5% stake in Alvotech, as well as exclusive rights to supply three of the firm’s biosimilar candidates in the Middle East and North Africa region.

“The total partnership value, including the purchase of new shares, an upfront license payment, along with subsequent milestone payments is...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business